Seoul National University

Sejong University

Siliconarts, Inc.

Jin Hur

Woo Chan Park

Hyo-Soo Kim

Young-Bae Park

Hyun-Jae Kang

Jong-Han Park

Hyun-Jai Cho

Jeehoon Kang

Jung-Kyu Han

Ji-Yeon Yun

Jae-Il Choi

Jin-A Kang

Jae Il Choi

Provided are a composition including a Kang AI 1 (KAI1) polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a use thereof, and more specifically, a composition including a KAI1 polypeptide or a gene encoding the same, for inhibiting angiogenesis, and a pharmaceutical composition for preventing and treating cancer. Further, KAI1, which is expressed in a pericyte rather than in an endotheliocyte, can inhibit angiogenesis by functioning as a negative angiogenic regulator, and thus the subject matter can inhibit angiogenesis due to a known angiogenesis factor by various methods such as a method using a supernatant in a pericyte which forcefully increases KAI1 or in which KAI1 is forcefully increased, a method using a KAI1 protein, or a method for inhibiting a Src-Pkc pathway provoking the degradation of KAI1. Further, the subject matter can identify the severity of a cancer patient by identifying the expression of KAI1 in a pericyte.

Composition comprising KA11 polypeptide or gene encoding the same for inhibiting angiogenesis, and use thereof

The present application discloses a method for producing peripheral blood stem cells with improved angiogenic properties through EPO or APS priming, and a use thereof. The cells produced according to the method of the present application induce angiogenesis, and thus can be effectively used for the regeneration of, or recovery from, various diseases requiring facilitation of angiogenesis, such as ischemic diseases occurring in the muscle, brain, heart, kidney, or large intestine, e.g. tissue damage, cerebral infarction, stroke, reperfusion injury, myocardial infarction, congestive heart failure, peripheral vascular obstruction, cardiac hypertrophy, low heart contraction, low heart dilatation, maladaptive cardiomegaly, systolic heart failure, diastolic heart failure, hypertensive heart failure, artery or mitral valve diseases, heart blood vessels with pulmonary valve diseases, or ischemic heart blood vessels, caused by ischemia.

Peripheral blood stem cells with improved angiogenic properties and use thereof

A ray tracing core includes a ray generation unit and a plurality of T&I (Traversal & Intersection) units with MIMD (Multiple Instruction stream Multiple Data stream) architecture. The ray generation unit generates at least one eye ray based on an eye ray generation information. The eye ray generation information includes a screen coordinate value. Each of the plurality of T&I units receives the at least one eye ray and checks whether there exists a triangle intersected with the received at least one eye ray. The triangle configures a space.

Ray tracing core and ray tracing chip having the same

A ray tracing core comprising a ray generation unit and a plurality of T&I (Traversal & Intersection) units with MIMD (Multiple Instruction stream Multiple Data stream) architecture is disclosed. The ray generation unit generates at least one eye ray based on an eye ray generation information. The eye ray generation information includes a screen coordinate value. Each of the plurality of T&I units receives the at least one eye ray and checks whether there exists a triangle intersected with the received at least one eye ray. The triangle configures a space.

The ray tracing apparatus for three-dimensional (3D) graphics includes a Central Processing Unit (CPU) for constructing a first Acceleration Structure (AS) for a static object, and creating a second dynamic object by performing a Level Of Detail (LOD) operation on the first dynamic object and a ray tracing core for performing ray tracing based on the first AS and a second AS for the second dynamic object. The CPU or the ray tracing core constructs the second AS for the second dynamic object.

Ray tracing apparatus and method

The present invention relates to a technique of using monocytic blood cells to effectively culture and proliferate blood adult stem cells and progenitor cells that only exist in small quantities to effectively obtain large quantities of stem cells. According to the present invention, the limitation of being able to derive only small quantities of stem cells from blood can be overcome, and the pluripotency of stem cells can easily be obtained.

Method for inducing human blood-born hematospheres through aggregate culture and expanding blood adult stem cells and progenitor cells, and stem cell prepared by the same

Growing community of inventors

Seoul, South Korea

Jin Hur